🔗 Visit the ClinicalTrials.gov page for NCT00195039
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Drug resistance in metastatic castration-resistant prostate cancer. | Nat Rev Clin Oncol | 2010 | 1.86 |
| 2 | Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. | Clin Cancer Res | 2013 | 1.51 |
| 3 | Overcoming drug resistance and treating advanced prostate cancer. | Curr Drug Targets | 2012 | 0.95 |
| 4 | Immunotherapy for prostate cancer: recent developments and future challenges. | Cancer Metastasis Rev | 2014 | 0.90 |
| 5 | Recent developments in prostate cancer biomarker research: therapeutic implications. | Br J Clin Pharmacol | 2011 | 0.86 |
| 6 | Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy. | J Clin Immunol | 2011 | 0.78 |